Video Latest - ecancer

CDK clinical trial results, benefit, side effects and costs

Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy

26 Oct 2016

Biomarkers of sensitivity and resistance

Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

26 Oct 2016

CDK4/6 inhibition: PALOMA2 versus MONALEESA2

Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

17 Oct 2016

LUME study of nintedanib finds improved PFS, but no overall survival boost

Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium

12 Oct 2016

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry

Dr Simon Chowdhury - Guy's Hospital, London, UK

10 Oct 2016

Lurbinectedin in BRCA 1/2 breast cancer

Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

10 Oct 2016

Highlights of ESMO 2016

Dr Andrés Cervantes - ESMO 2016 Scientific Chair

10 Oct 2016

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer

Prof John Robertson - University of Nottingham, Nottingham, UK

8 Oct 2016

Fulvestrant in FALCON trial improves PFS in advanced breast cancer

Dr Matthew Ellis - Washington University in St Louis, USA

8 Oct 2016

Prof Michael Seckl: Why attend Future Horizons in Lung Cancer?

Prof Michael Seckl - Imperial College London, London

17 Jul 2016

Breast and cervical cancer rates influenced by HRT, not contraceptive pill

Prof Valerie Beral - University of Oxford, Oxford, UK

30 Jun 2016

Editor's Choice for March 2016

Prof Gordon McVie - ecancer Editor

31 Mar 2016

Video